Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on AVINGTRANS PLC. We currently have 32 research reports from 4 professional analysts.
|28Nov16 01:07||RNS||Holding(s) in Company|
|23Nov16 07:00||RNS||Holding(s) in Company|
|22Nov16 07:00||RNS||Holding(s) in Company|
|21Nov16 07:00||RNS||Change of Nominated Advisor|
|18Nov16 03:11||RNS||Holding(s) in Company|
|18Nov16 03:05||RNS||Total Voting Rights|
|08Nov16 12:47||RNS||Result of Tender Offer and Director's Interests|
Frequency of research reports
Research reports on
N+1 Singer - Avingtrans - Result of tender offer
08 Nov 16
Avingtrans has announced the results of its tender offer, which was announced at the start of October. Under the offer c.9.7m shares were tendered, equivalent to c.35% of the shares in issue. These will be purchased at 200p, for a total price of c.£19.4m. This will leave the group with c.£28m for investment in the remaining Energy & Medical operations, to repeat its successful buy & build strategy.
N+1 Singer - Morning Song 04-10-2016
04 Oct 16
Trifast has reported solid trading for H1 17. Organic growth has continued at a similar level to FY16, driven by the group’s focus on increasing its penetration of its large OEM customers and winning new ones. Meanwhile weaker sterling has provided a material tailwind. We have increased our FY17 PBT and EPS forecasts by 4% to reflect updated FX assumptions, putting the shares on undemanding multiples of c.9.7x EV/EBITDA and 14.4x P/E. We have also increased our target price from 165p to 170p. Prospects remain positive and we reiterate our Buy recommendation.
N+1 Singer - Avingtrans - Tender offer details announced
03 Oct 16
Avingtrans has announced the terms of its proposed tender offer. Each shareholder is entitled to have up to 50% of their shareholding purchased at the tender price of 200p per share, with potential for additional shares to be purchased subject to the number of shares tendered by other shareholders. The tender offer period runs from 3rd October to 4th November.
29 Sep 16
Cambridge Cognition Holdings* (COG.L) | Edenville Energy (EDL.L) | Avingtrans (AVG.L) | Gaming Realms (GMR.L) | Redstone Connect (REDS.L) | Concurrent Technologies (CNC.L) | Porta Communications (PTCM.L) | Galantas Gold (GAL.L) | Range Resources (RRL.L) | Plutus Power Gen (PPG.L)
N+1 Singer - Morning Song 27-09-2016
27 Sep 16
Sarepta’s accelerated approval last week of EXONDYS 51™ for the treatment of around 13% of DMD patients is a significant milestone in the DMD market. We believe this sets a precedent for companies such as Summit and its utrophin modulation programme. Ezutromid, Summit’s lead DMD programme, commenced a Phase II proof-of-concept trial (PhaseOut DMD) in the UK in June. The first muscle biopsy data is expected Q2/Q3 2017. We take the opportunity to assess Summit’s offering in the context of recent developments in the DMD market and, in particular, we draw investors’ attention to the rapid share price appreciation of the main DMD plays.
Exceptional trading continues
08 Nov 16
Keywords has announced that the strong trading in localisation and audio services has continued into H216. In particular, the Synthesis business acquired in April continues to benefit from exceptionally strong trading. Full-year results are now expected to be materially ahead of consensus and we upgrade our FY16e EPS by 13%. Erring on the side of caution, we have not changed our FY17 estimates significantly. Nevertheless, we believe the company does have a platform to sustain double-digit earnings growth, and hence medium-/long-term prospects for further share appreciation remain good.
Panmure Morning Note 02-12-16
02 Dec 16
Today James Halstead will be holding its 101st AGM. Trading during the first part of FY17 has been mixed, with some notable challenges. However, movements in FX (i.e. weak sterling) is boosting reported earnings, offsetting UK volume trends and pricing pressures. Whilst earnings are likely to be second half weighted, the picture is in-line with expectations and we are leaving our FY17 PBT estimates unchanged (£47.4m in FY17 vs £45.4m FY16).
06 Dec 16
600 Group* (SIXH): Interim results: order book showing signs of improvement (CORP) | Real Good Food* (RGD): Commodity volatility impacts numbers (CORP) | Minds + Machines* (MMX): .vip goes live in China (CORP | Imaginatik* (IMTK): Interims (CORP) | iomart* (IOM): Quality business as usual (CORP) | Fulcrum (FCRM): Upgrades continue (BUY)
02 Dec 16
On 30 September 2016, when the company announced its full year results, it reported that the UK business had seen a slow start to the year, with particular weakness in repair and renewal spending by the NHS as well as “reticence” in the education sector. However, with the UK only representing about a third of the business, this weakness was expected to be more than offset by the positive effect of a weakened sterling on its overseas business, given the benefits for competitiveness and margins.
06 Dec 16
Acal’s H117 results reflected the weaker demand that was previously flagged combined with positive FX trends. Design & Manufacturing (D&M) continues to grow as a proportion of total revenues and profits and management has raised its targets for this part of the business. The company continues to consider further acquisitions, recently increasing its debt facility to support its growth strategy. The outlook for FY17 is unchanged – based on H117 order inflow, H217 is expected to be stronger and we leave our earnings forecasts substantially unchanged.